Skip to main content.

Yellow Fever

History, Epidemiology, and Vaccination Information

Page

Go to the Home page

Go to Main Menu

Go to Previous page

Go to Next page

Exit the course

Section Menu

Yellow Fever Vaccines

Administration

Things to Consider

Adverse Events

Mild Adverse Events

Severe Reactions

Hypersensitivity Reactions

Neurologic Disease

Viscerotropic Disease

Question 2

Monitoring Patients

Contraindications and Precautions

Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event associated with administration of the yellow fever vaccine. YEL-AVD is an illness similar to wild-type yellow fever, in which the vaccine virus proliferates in multiple organs, causing multiple organ dysfunction syndrome or multiorgan failure and death in at least 60% of cases. Since this complication was first recognized in 2001, more than 65 cases have been reported throughout the world. Viscerotropic disease has been reported in primary vaccinees only, with average onset 4 days (range: 0–8 days) after vaccination. Based on a recent analysis of VAERS data, the rate of YEL-AVD in travelers from the United States is 0.4/100,000 doses distributed.

 

Initial symptoms of YEL-AVD are nonspecific and can include the following: fever, malaise, headache, myalgia, vomiting, and diarrhea. More severe cases can progress to hepatic, renal, or respiratory insufficiency or failure; hypotension; thrombocytopenia; and coagulopathy.

 

There is no specific therapy for YEL-AVD. Treatment is supportive, once other diseases have been excluded. The diagnosis can be made by the presence of yellow fever vaccine virus detected by RT-PCR from serum or tissues.